Centessa Pharmaceuticals Files 8-K
Ticker: CNTA · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $250 million, $150,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, sec
TL;DR
Centessa dropped an 8-K, likely with company updates. Check for details.
AI Summary
Centessa Pharmaceuticals plc filed an 8-K on November 24, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the events reported, beyond its classification as a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934'. The company is incorporated in England and Wales and its principal executive offices are located in Altrincham, Cheshire, United Kingdom.
Why It Matters
This 8-K filing indicates Centessa Pharmaceuticals is reporting significant events or financial updates to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard procedural report without specific negative or positive financial disclosures, making the immediate risk level low.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- November 24, 2025 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation
- Altrincham, Cheshire (location) — Location of principal executive offices
FAQ
What specific events are being reported in this 8-K filing by Centessa Pharmaceuticals?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as item information, but does not specify the nature of these events within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 24, 2025.
Where is Centessa Pharmaceuticals plc incorporated?
Centessa Pharmaceuticals plc is incorporated in England and Wales.
What is the principal business address of Centessa Pharmaceuticals plc?
The principal business address is 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom.
What is the SEC file number for Centessa Pharmaceuticals plc?
The SEC file number for Centessa Pharmaceuticals plc is 001-40445.
Filing Stats: 1,137 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2025-11-24 07:24:48
Key Financial Figures
- $250 million — r more "at the market offerings", up to $250 million of the Company's American Depositary Sh
- $150,000 — es Agreement in an amount not to exceed $150,000. The Company is not obligated to make
Filing Documents
- d23843d8k.htm (8-K) — 33KB
- d23843dex11.htm (EX-1.1) — 244KB
- d23843dex51.htm (EX-5.1) — 57KB
- g23843g1120224650146.jpg (GRAPHIC) — 3KB
- 0001193125-25-292015.txt ( ) — 577KB
- cnta-20251124.xsd (EX-101.SCH) — 4KB
- cnta-20251124_def.xml (EX-101.DEF) — 14KB
- cnta-20251124_lab.xml (EX-101.LAB) — 24KB
- cnta-20251124_pre.xml (EX-101.PRE) — 15KB
- d23843d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 1.1 Amended and Restated Sales Agreement, dated November 24, 2025, by and between the Company and Leerink Partners LLC 5.1 Opinion of Goodwin Procter (UK) LLP 23.1 Consent of Goodwin Procter (UK) LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 24, 2025 CENTESSA PHARMACEUTICALS PLC By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer